739 related articles for article (PubMed ID: 28153099)
21. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
[TBL] [Abstract][Full Text] [Related]
22. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
[No Abstract] [Full Text] [Related]
23. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
24. Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.
Buatois V; Johnson Z; Salgado-Pires S; Papaioannou A; Hatterer E; Chauchet X; Richard F; Barba L; Daubeuf B; Cons L; Broyer L; D'Asaro M; Matthes T; LeGallou S; Fest T; Tarte K; Clarke Hinojosa RK; Genescà Ferrer E; Ribera JM; Dey A; Bailey K; Fielding AK; Eissenberg L; Ritchey J; Rettig M; DiPersio JF; Kosco-Vilbois MH; Masternak K; Fischer N; Shang L; Ferlin WG
Mol Cancer Ther; 2018 Aug; 17(8):1739-1751. PubMed ID: 29743205
[TBL] [Abstract][Full Text] [Related]
25. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.
Piccione EC; Juarez S; Liu J; Tseng S; Ryan CE; Narayanan C; Wang L; Weiskopf K; Majeti R
MAbs; 2015; 7(5):946-56. PubMed ID: 26083076
[TBL] [Abstract][Full Text] [Related]
26. CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
Bouwstra R; van Meerten T; Bremer E
Clin Transl Med; 2022 Aug; 12(8):e943. PubMed ID: 35908284
[TBL] [Abstract][Full Text] [Related]
27. CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma.
Zhu D; Hadjivassiliou H; Jennings C; Mikolon D; Ammirante M; Acharya S; Lloyd J; Abbasian M; Narla RK; Piccotti JR; Stamp K; Cho H; Hariharan K
MAbs; 2024; 16(1):2310248. PubMed ID: 38349008
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
[TBL] [Abstract][Full Text] [Related]
29. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
30. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
31. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
32. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
33. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
34. A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index.
Yang Y; Guo R; Chen Q; Liu Y; Zhang P; Zhang Z; Chen X; Wang T
Biotechnol Lett; 2018 May; 40(5):789-795. PubMed ID: 29600425
[TBL] [Abstract][Full Text] [Related]
35. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
[TBL] [Abstract][Full Text] [Related]
36. G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy.
Ribeiro ML; Profitós-Pelejà N; Santos JC; Blecua P; Reyes-Garau D; Armengol M; Fernández-Serrano M; Miskin HP; Bosch F; Esteller M; Normant E; Roué G
Front Immunol; 2023; 14():1130052. PubMed ID: 37153563
[TBL] [Abstract][Full Text] [Related]
37. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
[TBL] [Abstract][Full Text] [Related]
38. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
39. Selective CD47 targeting with a bispecific antibody.
Ferlin W; Masternak K; Shang L
Cancer Immunol Immunother; 2021 Apr; 70(4):1161-1162. PubMed ID: 33388996
[No Abstract] [Full Text] [Related]
40. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
